Reported 2 days ago
Corcept Therapeutics Incorporated (NASDAQ:CORT), a California-based firm specializing in cortisol modulation, is advancing its drug pipeline while managing risk. The company has completed a Phase 1 study on the safety of dazucorilant and submitted a new drug application for relacorilant to the U.S. FDA, building on positive Phase 3 trial results. With over 30 clinical-stage compounds across various medical fields, analysts continue to endorse the stock for its low-risk, high-growth potential, despite some alternative investments showing greater upside.
Source: YAHOO